Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKinsey
Colorcon
Harvard Business School
Mallinckrodt

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR LEVOMILNACIPRAN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Levomilnacipran Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00969150 ↗ Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder Completed Forest Laboratories Phase 3 2009-09-01 The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
NCT00969709 ↗ Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder Completed Forest Laboratories Phase 3 2009-09-01 The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
NCT01034462 ↗ Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder Completed Forest Laboratories Phase 3 2009-12-01 The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder
NCT01085812 ↗ Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder Completed Forest Laboratories Phase 3 2010-03-01 The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
NCT01254305 ↗ Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder Completed Forest Laboratories Phase 2 2011-04-01 The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
NCT01377194 ↗ Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder Completed Forest Laboratories Phase 3 2011-06-01 The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Levomilnacipran Hydrochloride

Condition Name

Condition Name for Levomilnacipran Hydrochloride
Intervention Trials
Major Depressive Disorder 11
Tobacco Use Disorder 1
Depression 1
Depressive Disorder, Major 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Levomilnacipran Hydrochloride
Intervention Trials
Depressive Disorder, Major 12
Depressive Disorder 12
Depression 12
Disease 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Levomilnacipran Hydrochloride

Trials by Country

Trials by Country for Levomilnacipran Hydrochloride
Location Trials
United States 167
Canada 7
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Levomilnacipran Hydrochloride
Location Trials
New York 9
Florida 9
California 9
Illinois 9
Georgia 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Levomilnacipran Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Levomilnacipran Hydrochloride
Clinical Trial Phase Trials
Phase 4 4
Phase 3 8
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Levomilnacipran Hydrochloride
Clinical Trial Phase Trials
Completed 12
Active, not recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Levomilnacipran Hydrochloride

Sponsor Name

Sponsor Name for Levomilnacipran Hydrochloride
Sponsor Trials
Forest Laboratories 9
Allergan 2
University of California, Los Angeles 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Levomilnacipran Hydrochloride
Sponsor Trials
Industry 11
Other 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Dow
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.